Lytix Biopharma AS
F:6BG
Income Statement
Earnings Waterfall
Lytix Biopharma AS
Income Statement
Lytix Biopharma AS
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
11
+683%
|
1
-87%
|
1
+5%
|
4
+169%
|
4
N/A
|
15
+264%
|
14
-1%
|
11
-26%
|
11
+4%
|
1
-95%
|
1
N/A
|
|
| Operating Income | ||||||||||||||||
| Operating Expenses |
(48)
|
(62)
|
(59)
|
(60)
|
(77)
|
(77)
|
(102)
|
(105)
|
(101)
|
(106)
|
(93)
|
(94)
|
(107)
|
(91)
|
(75)
|
|
| Selling, General & Administrative |
(32)
|
(21)
|
(24)
|
(24)
|
(20)
|
(23)
|
(24)
|
(26)
|
(24)
|
(25)
|
(22)
|
(20)
|
(23)
|
(21)
|
(20)
|
|
| Research & Development |
(29)
|
(35)
|
(42)
|
(42)
|
(46)
|
(56)
|
(68)
|
(68)
|
(63)
|
(68)
|
(56)
|
(60)
|
(73)
|
(59)
|
(42)
|
|
| Depreciation & Amortization |
0
|
0
|
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
|
| Other Operating Expenses |
12
|
(6)
|
7
|
6
|
(10)
|
2
|
(10)
|
(12)
|
(12)
|
(12)
|
(13)
|
(12)
|
(11)
|
(11)
|
(12)
|
|
| Operating Income |
(48)
N/A
|
(62)
-30%
|
(59)
+5%
|
(58)
+1%
|
(66)
-13%
|
(75)
-15%
|
(100)
-33%
|
(101)
-1%
|
(97)
+4%
|
(91)
+6%
|
(79)
+13%
|
(83)
-6%
|
(96)
-15%
|
(91)
+5%
|
(74)
+18%
|
|
| Pre-Tax Income | ||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
10
|
0
|
0
|
0
|
9
|
1
|
1
|
1
|
2
|
2
|
2
|
|
| Total Other Income |
(0)
|
(1)
|
8
|
15
|
(0)
|
15
|
9
|
3
|
(0)
|
4
|
1
|
0
|
(0)
|
0
|
(0)
|
|
| Pre-Tax Income |
(48)
N/A
|
(63)
-31%
|
(51)
+19%
|
(43)
+15%
|
(56)
-30%
|
(60)
-8%
|
(91)
-51%
|
(99)
-8%
|
(88)
+11%
|
(86)
+2%
|
(76)
+12%
|
(81)
-6%
|
(94)
-17%
|
(89)
+6%
|
(73)
+18%
|
|
| Net Income | ||||||||||||||||
| Income from Continuing Operations |
(48)
|
(63)
|
(51)
|
(43)
|
(56)
|
(60)
|
(91)
|
(99)
|
(88)
|
(86)
|
(76)
|
(81)
|
(94)
|
(89)
|
(73)
|
|
| Net Income (Common) |
(48)
N/A
|
(63)
-31%
|
(51)
+19%
|
(43)
+15%
|
(56)
-30%
|
(60)
-8%
|
(91)
-51%
|
(99)
-8%
|
(88)
+11%
|
(86)
+2%
|
(76)
+12%
|
(81)
-6%
|
(94)
-17%
|
(89)
+6%
|
(73)
+18%
|
|
| EPS (Diluted) |
-1.24
N/A
|
-1.62
-31%
|
-1.27
+22%
|
-1.11
+13%
|
-1.39
-25%
|
-1.5
-8%
|
-2.28
-52%
|
-2.45
-7%
|
-2.16
+12%
|
-2.09
+3%
|
-1.68
+20%
|
-1.61
+4%
|
-1.74
-8%
|
-1.3
+25%
|
-1.06
+18%
|
|